Acute myeloid leukemia

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

Wednesday, December 1, 2021 - 2:00pm

These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).

Key Points: 
  • These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).
  • These in vitro data have been replicated in the first patient treated with three, weekly doses of INKmune for high risk MDS.
  • Details of the presentations are as follows:
    Natural killer (NK) cells are innate lymphocytes that target virus-infected and tumor cells.
  • Their unique phenotypic and gene expression signatures suggest a novel and distinct form of memory-like NK cell governed by tumor-specific signaling pathways.

Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

Wednesday, December 1, 2021 - 1:35pm

HOUSTON, Dec. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the Company's Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. With this IND now cleared, Moleculin plans to initiate a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1122 in adult patients with GBM.

Key Points: 
  • The Company believes WP1122 has significant potential as both an antiviral therapy and as a cancer therapy.
  • Moleculin recently announced its plans to initiate a Phase 1a clinical trial of WP1122 in healthy volunteers in the United Kingdom to facilitate future testing in COVID-19 patients.
  • This new US IND sets the stage for parallel development of WP1122 as a cancer therapy.
  • "This IND underscores our dual pronged approach to the development of WP1122 for the treatment of both certain types of cancers and viruses.

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Wednesday, December 1, 2021 - 12:00pm

(Nasdaq: TSVT), an emerging immuno-oncology company, today reported financial results and recent highlights for the third quarter ended September 30, 2021.

Key Points: 
  • (Nasdaq: TSVT), an emerging immuno-oncology company, today reported financial results and recent highlights for the third quarter ended September 30, 2021.
  • The results for the period ended September 30, 2021, have been prepared on a carve-out basis and are derived from bluebird bio, Inc.s consolidated financial statements and accounting records.
  • 2seventy bio is a trademark of 2seventy bio, Inc.
  • All information in this press release is as of the date of the release, and 2seventy bio undertakes no duty to update this information unless required by law.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura Oncology, Inc. - KURA

Wednesday, December 1, 2021 - 12:41am

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA).

Key Points: 
  • NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ:KURA).
  • Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext.
  • The investigation concerns whether Kura and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the Treatment of Newly-Diagnosed Glioblastoma Patients

Tuesday, November 30, 2021 - 7:01pm

This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.

Key Points: 
  • This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.
  • ITIs dendritic cell vaccine is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.
  • This dendritic cell vaccine is then returned to the patient.
  • The ATTAC-II study ( NCT02465268 ) is a Phase II randomized, placebo-controlled clinical trial enrolling patients with newly diagnosed GBM that will explore whether dendritic cell (DC) vaccines, including ITI-1000, targeting the CMV antigen pp65 improves survival.

MANA Therapeutics Announces Final Closing of Series A and Closing of Venture Debt Facility

Tuesday, November 30, 2021 - 11:00am

MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the final closing of its Series A financing, bringing the total raised to $42 million.

Key Points: 
  • MANA Therapeutics , a clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, today announced the final closing of its Series A financing, bringing the total raised to $42 million.
  • In addition, MANA closed a $7.5 million venture debt facility with Silicon Valley Bank with an initial tranche of $5 million available immediately.
  • It will also permit building out our pipeline of MANA-512 candidates, which will apply new sets of antigens to the EDIFY platform.
  • MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes for cancer patients.

EXIT Realty’s Charitable Support Reaches $6.8 Million

Monday, November 29, 2021 - 7:23pm

Tami Bonnell, Co-Chair of EXIT Realty Corp. International, today announced that the corporate charitable contributions to-date have reached $6.8 million furthering the companys commitment in support of its agents fundraising efforts.

Key Points: 
  • Tami Bonnell, Co-Chair of EXIT Realty Corp. International, today announced that the corporate charitable contributions to-date have reached $6.8 million furthering the companys commitment in support of its agents fundraising efforts.
  • Our associates support charities across a wide spectrum of needs, including medical support and research, childrens services, community and veteran support, animal welfare and more, said Bonnell.
  • About EXIT Realty: EXIT Realty is a company founded and built on human potential.
  • A portion of every transaction fee received by EXIT Realty Corp. International is applied to its charitable fund, and to-date, $6.8 million has been allocated to charity.

Bionano Genomics Appoints Dr. Keith Gligorich, Seasoned Leader in CLIA-Certified CAP-Accredited Lab Operations, as VP Operations for Bionano Laboratories

Monday, November 29, 2021 - 1:00pm

Keith was most recently with Guarant Health where he led the build-out of Guardants CLIA-certified, CAP-accredited laboratory for blood-based early cancer detection testing.

Key Points: 
  • Keith was most recently with Guarant Health where he led the build-out of Guardants CLIA-certified, CAP-accredited laboratory for blood-based early cancer detection testing.
  • He has over a decade of experience in molecular diagnostic test development and laboratory operations.
  • Prior to joining Guardant Health, Keith held leadership roles at ARUP Laboratories, Navican Genomics and Cradle Genomics.
  • We look forward to Keith leading the planned expansion of our offering to include services and LDTs under CLIA-certification and CAP-accreditation within Bionano Laboratories.

Aptose to Hold Corporate Update Monday, December 13th

Monday, November 29, 2021 - 12:30pm

SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Monday, December 13, 2021 at 5:30 PM ET, in conjunction with participation at the 2021 ASH Annual Meeting. The event will include a review of HM43239 data highlighted in an oral presentation at ASH, as well as the up-to-date clinical status of luxeptinib. HM43239 is an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML). Luxeptinib is an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS)

Key Points: 
  • As announced previously, the abstracts accepted for presentation at ASH are listed below and can be viewed online at the ASH conference website.
  • Note that the poster presentations will include additional data not found in the abstracts.
  • Oral Presentation Session Date & Time: Monday, December 13, 2021, 4:00 PM ET
    Session Name: 616.
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.

Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer

Thursday, November 25, 2021 - 8:00am

DUBLIN, Nov. 25, 2021 /PRNewswire/ --Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer.

Key Points: 
  • DUBLIN, Nov. 25, 2021 /PRNewswire/ --Priothera Ltd, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, mocravimod, announces the appointment of Elisabeth Kueenburg, M.D., as Chief Medical Officer.
  • "The breadth of knowledge Elisabeth has gained working at Celgene, alongside her extensive clinical experience, makes her a crucial addition to our team," said Florent Gros, Co-Founder and CEO of Priothera.
  • "I am pleased to join Priothera at such an important stage of its development," said Dr. Kueenburg.
  • Dr. Kueenburg brings significant drug development and medical affairs experience from her years at Celgene where she most recently served as Clinical Development Lead.